Straumann Holding AG posted a first-half net profit of CHF250.7 million, up 5.2% from a year earlier but below the CHF257.2 million consensus estimate compiled by S&P Global Visible Alpha. Revenue increased 2.3% in Swiss francs to CHF1.38 billion, marginally ahead of the CHF1.37 billion forecast.
Core net profit, excluding non-recurring items, rose 15.7% to CHF262 million. The company attributed the shortfall to CHF18 million in legal costs tied to ongoing patent and antitrust litigation with Align Technology and CHF13.9 million in M&A-related amortization and contingent-consideration effects.
Organic revenue growth accelerated to 8.5% in the second quarter from 7.8% in the first half, driven by gains in EMEA and North America, each expanding more than 8%. Latin America delivered double-digit growth, while APAC returned to growth as China’s patient flows improved and distributor inventories stabilized.
Straumann maintained its full-year 2026 guidance for high-single-digit organic revenue growth and core EBIT-margin expansion of 140 to 170 basis points at constant 2025 exchange rates, a target raised in June. The company also noted that China’s volume-based procurement (VBP) 2.0 process could begin in the second half of the year, with implementation planned for early 2027.
Shares fell 6.3% to CHF93.38, the lowest level since June 16, after Jefferies retained a Hold rating with a CHF110 price target.
